Weekly Digest – June 2026 Weekly Digest – June 2026 16 June 2026: Zai Lab’s Zocilurtatug pelitecan receives EMA Orphan Drug Designation for pulmonary Neuroendocrine carcinoma Zai Lab has received Orphan Drug Designation from the European Medicines Agency for Zocilurtatug […]
Weekly Digest – June 2026 Weekly Digest – June 2026 17 June 2026: FDA Accepts sBLA for Genentech’s Lunsumio and Polivy combination in relapsed/refractory Large B-cell lymphoma Genentech has announced that the U.S. FDA has accepted a supplemental Biologics License […]
Weekly Digest – June 2026 Weekly Digest – June 2026 12 June 2026: Oncopeptides submits EMA application for Pepaxti label expansion to third-line treatment Oncopeptides has submitted a type 2 variation application to the European Medicines Agency seeking to expand […]
Weekly Digest – June 2026 Weekly Digest – June 2026 17 June 2026: Henlius’ HLX43 in combination with Serplulimab phase 2 NSCLC trial approved in Australia Henlius has received approval from Australia’s Human Research Ethics Committee, with acknowledgment from the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Akeso’s HER3 ADC AK138D1 in combination with Ivonescimab phase 1/2 Breast cancer trial enrolls first patient Akeso has announced the enrollment of the first patient in the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 15 June 2026: Lonza grants Antharis exclusive license to develop dual-payload ADCs for GI cancers Antharis Therapeutics has entered into an exclusive, target-specific licensing agreement with Lonza to develop next-generation […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: China NMPA approves Zai Lab’s TIVDAK for recurrent or metastatic Cervical cancer Zai Lab has received approval from China’s National Medical Products Administration for TIVDAK for the […]
Weekly Digest – June 2026 Weekly Digest – June 2026 11 June 2026: CDSCO approves Trastuzumab deruxtecan plus Pertuzumab for first-line HER2-positive metastatic Breast cancer AstraZeneca Pharma India has received CDSCO approval for Enhertu in combination with pertuzumab as a […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: China NMPA grants IND clearance to ADRX-0405 for advanced Solid tumors including Prostate cancer Adcentrx Therapeutics has received Investigational New Drug clearance from China’s National Medical Products […]
Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Merck and Gilead discontinue phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy plus Keytruda in 1L metastatic NSCLC Merck and Gilead have announced the discontinuation of the phase 3 […]
